Roche is launching a new genomic profiling kit that lets cancer researchers explore tumors without having to send tissue samples to centralized laboratories, the Swiss drugmaker said on Oct. 25.

Atea Pharmaceuticals Inc.’s experimental Covid-19 antiviral pill being developed with Roche failed to help patients with mild and moderate Covid-19 in a small study of mostly low-risk patients, driving the Boston-based drugmaker’s shares down more than 65 percent on Oct. 19.

Roche’s Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Oct. 13

The U.S. Food and Drug Administration awarded Roche’s Alzheimer’s disease drug candidate Breakthrough Therapy Designation, bringing the IgG1 antibody gantenerumab closer to finally receiving full FDA approval. 

As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.

A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.

The U.S. Food and Drug Administration on Sept. 20 approved South Korean drugmaker Samsung Bioepis Co. Ltd. and Biogen Inc.’s biosimilar rival to Roche Holding AG’s blockbuster eye medicine Lucentis.

Pancreatic cancer has the lowest survival rate of the most common cancers as less than 10 percent of patients survive longer than five years, largely due to most cases being diagnosed at a late stage. A collaboration between NovoCure and Roche hopes to improve those odds.

Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest. 

Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.